Lundbeck completes randomization in Phase III epilepsy trial
July 21, 2026 | 11:28
Lundbeck announced the last patient has been randomized in DEEp OCEAN, a global Phase III trial evaluating bexicaserin for seizures in developmental and epileptic encephalopathies.
Mobile Version